The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 12, 2019

Filed:

Apr. 28, 2017
Applicant:

Asana Biosciences, Llc, Lawrenceville, NJ (US);

Inventors:

Scott K. Thompson, Phoenixville, PA (US);

Roger A. Smith, Chester Springs, PA (US);

Sanjeeva Reddy, Chester Springs, PA (US);

Tyler M. John, Phoenixville, PA (US);

Vijay Kumar Nyavanandi, Hyderabad, IN;

Subramanya Hoshalli, Bangalore, IN;

Vijay Potluri, Hyderabad, IN;

Sunil Kumar Panigrahi, Orissa, IN;

Prabhakara Rao Nadipalli, Bachupally, IN;

Saumitra Sengupta, Kolkata, IN;

Assignee:

Asana BioSciences, LLC, Lawrenceville, NJ (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 239/94 (2006.01); C07D 413/14 (2006.01); C07D 401/04 (2006.01); C07D 401/12 (2006.01); C07D 401/14 (2006.01); A61K 31/5377 (2006.01); C07D 403/04 (2006.01); C07D 409/14 (2006.01); C07D 471/04 (2006.01); C07D 519/00 (2006.01); A61K 45/06 (2006.01); G01N 33/50 (2006.01); G01N 33/574 (2006.01);
U.S. Cl.
CPC ...
A61K 31/5377 (2013.01); A61K 45/06 (2013.01); C07D 239/94 (2013.01); C07D 401/04 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 403/04 (2013.01); C07D 409/14 (2013.01); C07D 413/14 (2013.01); C07D 471/04 (2013.01); C07D 519/00 (2013.01); G01N 33/5011 (2013.01); G01N 33/57496 (2013.01);
Abstract

The present application provides novel quinazolines and azaquinazolines and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in for co-regulating RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways by administering a therapeutically effective amount of one or more of the compounds of formula (I), wherein X, Y, T and R, and Rto Rare defined herein, to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer.


Find Patent Forward Citations

Loading…